MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ
73.31
+0.59
+0.81%
After Hours: 73.20 -0.11 -0.15% 16:05 12/05 EST
OPEN
72.02
PREV CLOSE
72.72
HIGH
73.99
LOW
71.99
VOLUME
722.30K
TURNOVER
0
52 WEEK HIGH
74.00
52 WEEK LOW
37.82
MARKET CAP
4.46B
P/E (TTM)
-7.9667
1D
5D
1M
3M
1Y
5Y
Blueprint Medicines Corp: Statement of changes in beneficial ownership of securities
Press release · 1d ago
Blueprint Medicines Corp: Report of proposed sale of securities
Press release · 1d ago
XBI, MRTX, CRSP, BPMC: Large Outflows Detected at ETF
NASDAQ · 2d ago
Weekly Report: what happened at BPMC last week (1127-1201)?
Weekly Report · 2d ago
Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
NASDAQ · 5d ago
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
NASDAQ · 11/29 16:30
Blueprint Medicines Corp: Statement of changes in beneficial ownership of securities
Press release · 11/29 00:02
Commit To Buy Blueprint Medicines At $55, Earn 8% Using Options
NASDAQ · 11/28 18:24
More
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Webull offers Blueprint Medicines Corp stock information, including NASDAQ: BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.